E R Dubberke1, K A Reske1, M A Olsen1, K Bommarito1, A A Cleveland2, F P Silveira3, M G Schuster4, C A Kauffman5, R K Avery6, P G Pappas7, T M Chiller2. 1. Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA. 2. Centers for Disease Control and Prevention, Atlanta, GA, USA. 3. Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, USA. 4. University of Pennsylvania, Philadelphia, PA, USA. 5. VA Ann Arbor Healthcare System, University of Michigan Medical School, Ann Arbor, MI, USA. 6. Johns Hopkins University, Baltimore, MD, USA. 7. University of Alabama at Birmingham, Birmingham, AL, USA.
Abstract
BACKGROUND: Clostridium difficile infection (CDI) is a common complication of lung and allogeneic hematopoietic cell (HCT) transplant, but the epidemiology and outcomes of CDI after transplant are poorly described. METHODS: We performed a prospective, multicenter study of CDI within 365 days post-allogeneic HCT or lung transplantation. Data were collected via patient interviews and medical chart review. Participants were followed weekly in the 12 weeks post-transplant and while hospitalized and contacted monthly up to 18 months post-transplantation. RESULTS: Six sites participated in the study with 614 total participants; 4 enrolled allogeneic HCT (385 participants) and 5 enrolled lung transplant recipients (229 participants). One hundred and fifty CDI cases occurred within 1 year of transplantation; the incidence among lung transplant recipients was 13.1% and among allogeneic HCTs was 31.2%. Median time to CDI was significantly shorter among allogeneic HCT than lung transplant recipients (27 days vs 90 days; P = .037). CDI was associated with significantly higher mortality from 31 to 180 days post-index date among the allogeneic HCT recipients (Hazard ratio [HR] = 1.80; P = .007). There was a trend towards increased mortality among lung transplant recipients from 120 to 180 days post-index date (HR = 4.7, P = .09). CONCLUSIONS: The epidemiology and outcomes of CDI vary by transplant population; surveillance for CDI should continue beyond the immediate post-transplant period.
BACKGROUND:Clostridium difficileinfection (CDI) is a common complication of lung and allogeneic hematopoietic cell (HCT) transplant, but the epidemiology and outcomes of CDI after transplant are poorly described. METHODS: We performed a prospective, multicenter study of CDI within 365 days post-allogeneic HCT or lung transplantation. Data were collected via patient interviews and medical chart review. Participants were followed weekly in the 12 weeks post-transplant and while hospitalized and contacted monthly up to 18 months post-transplantation. RESULTS: Six sites participated in the study with 614 total participants; 4 enrolled allogeneic HCT (385 participants) and 5 enrolled lung transplant recipients (229 participants). One hundred and fifty CDI cases occurred within 1 year of transplantation; the incidence among lung transplant recipients was 13.1% and among allogeneic HCTs was 31.2%. Median time to CDI was significantly shorter among allogeneic HCT than lung transplant recipients (27 days vs 90 days; P = .037). CDI was associated with significantly higher mortality from 31 to 180 days post-index date among the allogeneic HCT recipients (Hazard ratio [HR] = 1.80; P = .007). There was a trend towards increased mortality among lung transplant recipients from 120 to 180 days post-index date (HR = 4.7, P = .09). CONCLUSIONS: The epidemiology and outcomes of CDI vary by transplant population; surveillance for CDI should continue beyond the immediate post-transplant period.
Authors: Janet T Lee; Rosemary F Kelly; Marshall I Hertz; Jordan M Dunitz; Sara J Shumway Journal: J Heart Lung Transplant Date: 2013-07-23 Impact factor: 10.247
Authors: Mini Kamboj; Kun Xiao; Anna Kaltsas; Yao-Ting Huang; Janet Sun; Dick Chung; Saliangi Wu; Anna Sheahan; Kent Sepkowitz; Ann A Jakubowski; Genovefa Papanicolaou Journal: Biol Blood Marrow Transplant Date: 2014-06-25 Impact factor: 5.742
Authors: Suresh Paudel; Ioannis M Zacharioudakis; Fainareti N Zervou; Panayiotis D Ziakas; Eleftherios Mylonakis Journal: PLoS One Date: 2015-04-17 Impact factor: 3.240
Authors: Erik R Dubberke; Margaret A Olsen; Dustin Stwalley; Ciarán P Kelly; Dale N Gerding; Yinong Young-Xu; Cedric Mahé Journal: PLoS One Date: 2016-02-09 Impact factor: 3.240
Authors: Erik R Dubberke; Kimberly A Reske; Margaret A Olsen; Kerry M Bommarito; Sondra Seiler; Fernanda P Silveira; Tom M Chiller; John DiPersio; Victoria J Fraser Journal: Transplant Direct Date: 2017-03-17
Authors: Alex Ganetsky; Jennifer H Han; Mitchell E Hughes; Daria V Babushok; Noelle V Frey; Saar I Gill; Elizabeth O Hexner; Alison W Loren; Selina M Luger; James K Mangan; Mary Ellen Martin; Jacqueline Smith; Craig W Freyer; Cheryl Gilmar; Mindy Schuster; Edward A Stadtmauer; David L Porter Journal: Clin Infect Dis Date: 2019-05-30 Impact factor: 9.079
Authors: Stephen M Maurer; Kathleen A Linder; Carol A Kauffman; Philip J McDonald; Jonathan Arcobello; Jon Velasco; Pranatharthi H Chandrasekar; Sanjay G Revankar; Marisa H Miceli Journal: Bone Marrow Transplant Date: 2022-09-23 Impact factor: 5.174